Araştırma Makalesi

Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer's Gold Data

Cilt: 21 Sayı: 4 29 Aralık 2025
PDF İndir
EN

Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer's Gold Data

Öz

This study aimed to experimentally compare dosimetric measurement data obtained after linac replacement in a Tomotherapy HiArt system with the "gold data" provided by the manufacturer, according to the acceptance criteria recommended by AAPM TG-148. Energy quality (TPR1.5/10), percentage depth dose (PDD), transverse and longitudinal beam profiles, and patient treatment plan quality assurance (QA) measurements were performed and compared with gold data. The difference between the gold and measured data in the energy quality measurement was 0.5%. In the PDD measurements, the difference in dmax values remained at a maximum of 0.9 mm, and the PDD20/10 ratio remained below 1%. Agreement within the 1% tolerance limits was also observed in the transverse and longitudinal profiles. Furthermore, the patient QA measurements were in agreement with the results obtained using the previous linac. The findings demonstrated that all measurements remained within the TG-148 criteria, indicating that linac replacement did not significantly affect system performance. These results confirmed that the TomoTherapy HiArt system provides reliable and accurate dosimetric measurements following linac replacement, ensuring consistent and high-quality patient treatment delivery.

Anahtar Kelimeler

Kaynakça

  1. [1]. Balog J, Olivera G, Kapatoes J. 2003. Clinical helical tomotherapy commissioning dosimetry. Med Phys;30(12):3097–106.
  2. [2]. Jeraj R, Mackie TR, Balog J, John Balog, 2004. Gustavo Olivera, Dave Pearson, Jeff Kapatoes, Ken Ruchala, Paul Reckwerdt. Radiation characteristics of helical tomotherapy. Med Phys; 31(2):396–404.
  3. [3]. Langen KM, Papanikolaou N, Balog J, Crilly R, Followill D, Goddu SM, Grant W, Olivera G, Ramsey CR, Shi C. 2010. QA for helical tomotherapy: report of the AAPM Task Group 148. Med Phys. Sep;37(9):4817-53.
  4. [4]. Zhao YL, Mackenzie M, Kirkby C, Fallone BG. 2008. Monte Carlo calculation of helical tomotherapy dose delivery. Med Phys; 35(8):3491–500.
  5. [5]. Jean L. Peng,a Michael S. Ashenafi, Daniel G. McDonald, Kenneth N. Vanek. 2015. Assessment of a three-dimensional (3D) water scanning system for beam commissioning and measurements on a helical tomotherapy unit. Journal Of Applıed Clınıcal Medıcal Physıcs, Volume 16, Number 1.
  6. [6]. Göksel E, Barlaz Us S, Akdeniz Y, Bozca R, Elçim Y, Gani Z, Güray G, Dede Karakoç N, Nalbant N, Toksoy T, Yeşil A. 2024. Guide For Quality Control and Quality Assurance Tests in Tomotherapy/Radixact Systems. Turk J Oncol 2024;39(Supp 1):31–5.
  7. [7]. Günhan B. 2010. Helikal Tomoterapi’de Hasta Kalite Kontrolünde Dozimetrik Yöntemlerin Karşılaştırılması. İstanbul Ünversitesi Sağlık Bilimleri Enstitüsü Doktora Tezi İstanbul.
  8. [8]. Sharma SD. 2011. Unflattened photon beams from the standard flattening filter free accelerators for radiotherapy: Advantages, limitations and challenges Med Phys. 2011 Jul-Sep;36(3):123–125.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Biyomedikal Enstrümantasyon

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

29 Aralık 2025

Gönderilme Tarihi

4 Şubat 2025

Kabul Tarihi

29 Mayıs 2025

Yayımlandığı Sayı

Yıl 2025 Cilt: 21 Sayı: 4

Kaynak Göster

APA
Kaya Pepele, E. (2025). Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data. Celal Bayar University Journal of Science, 21(4), 70-78. https://doi.org/10.18466/cbayarfbe.1633397
AMA
1.Kaya Pepele E. Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data. Celal Bayar University Journal of Science. 2025;21(4):70-78. doi:10.18466/cbayarfbe.1633397
Chicago
Kaya Pepele, Eda. 2025. “Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data”. Celal Bayar University Journal of Science 21 (4): 70-78. https://doi.org/10.18466/cbayarfbe.1633397.
EndNote
Kaya Pepele E (01 Aralık 2025) Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data. Celal Bayar University Journal of Science 21 4 70–78.
IEEE
[1]E. Kaya Pepele, “Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data”, Celal Bayar University Journal of Science, c. 21, sy 4, ss. 70–78, Ara. 2025, doi: 10.18466/cbayarfbe.1633397.
ISNAD
Kaya Pepele, Eda. “Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data”. Celal Bayar University Journal of Science 21/4 (01 Aralık 2025): 70-78. https://doi.org/10.18466/cbayarfbe.1633397.
JAMA
1.Kaya Pepele E. Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data. Celal Bayar University Journal of Science. 2025;21:70–78.
MLA
Kaya Pepele, Eda. “Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data”. Celal Bayar University Journal of Science, c. 21, sy 4, Aralık 2025, ss. 70-78, doi:10.18466/cbayarfbe.1633397.
Vancouver
1.Eda Kaya Pepele. Assessing Tomotherapy Performance Post-Linac Replacement: A Dosimetric Comparison with Manufacturer’s Gold Data. Celal Bayar University Journal of Science. 01 Aralık 2025;21(4):70-8. doi:10.18466/cbayarfbe.1633397